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Abstract
Background—The increasing reports of Middle East Respiratory Syndrome (MERS) caused by 
MERS coronavirus (MERS-CoV) from many countries emphasize its importance for international 
travel. Muslim pilgrimages of Hajj and Umrah involve mass gatherings of international travellers. 
We set out to assess the presence of influenza and MERS-CoV in Hajj/Umrah returnees with acute 
respiratory infection.
Methods—Disembarking passengers (n = 8753) from Saudi Arabia (October 2014 to April 2015) 
were interviewed for the presence of respiratory symptoms; 977 (11%) reported symptoms and 
300 (age 26 –90, median 60 years; 140 male) consented to participate in the study. After recording 
clinical and demographic data, twin swabs (nasopharyngeal and throat) were collected from each 
participant, pooled in viral transport media and tested by real-time RT PCR for MERS-CoV and 
influenza A and B viruses and their subtypes.
Results—The participants had symptoms of 1–15 days (median 5d); cough (90%) and nasal 
discharge (86%) being the commonest. None of the 300 participants tested positive for MERS-
CoV; however, 33 (11%) tested positive for influenza viruses (A/H3N2 = 13, A/H1N1pdm09 = 9 
and B/Yamagata = 11). Eighteen patients received oseltamivir. No hospitalizations were needed 
and all had uneventful recovery.
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Conclusion—Despite a high prevalence of acute respiratory symptoms, MERS coV was not 
seen in returning pilgrims from Hajj and Umrah. However detection of flu emphasises preventive 
strategies like vaccination.
Keywords
Middle East Respiratory Virus syndrome; Pilgrimage; Hajj; Acute respiratory infection
1. Introduction
Middle East Respiratory Syndrome (MERS) is a highly lethal viral respiratory illness that is 
caused by a novel, single-stranded beta-coronavirus (MERS-CoV), first reported in Saudi 
Arabia during 2012 in a patient with acute pneumonia and renal failure [1]. As of April 
2016, the WHO reported 1728 laboratory-confirmed cases of MERS-CoV, and at least 624 
deaths [2]. All known reported cases have been associated with nine affected countries in or 
near the Arabian Peninsula. Twenty-seven countries in Europe, USA, Africa and Asia have 
also reported cases, among people who travelled from the Middle East or their contacts 
[2,3]; but none have been reported from India. In 2015, the largest outbreak of MERS-CoV 
outside of the Middle East (186 infections and 36 deaths) was reported in the Republic of 
Korea that was traced to a single person returning from Saudi Arabia [4].
Although the reservoir and method of transmission remain incompletely characterized, 
MERS-CoV appears to be transmitted through respiratory droplets and in all probability has 
zoonotic repositories in dromedary camels with possible origin in bats [1,3]. Human to 
human transmission requires close contact with infected persons [1,4]. Muslim pilgrimages 
of Hajj and Umrah, draw millions of people (>2.0 and > 5.0 million, respectively in 2014) to 
Mecca annually. Hajj is performed in the 12th month of the lunar calendar and Umrah 
throughout the year. A high risk of acquisition of respiratory tract infections has been 
reported during these pilgrimages [5] which has implications of subsequent international 
transmission to other countries [6,7]. Kashmir valley in the northern Indian state of Jammu 
and Kashmir receives 6–7 thousand Hajj and 25–30 thousand Umrah returnees every year. 
We report our findings of screening the returning pilgrims with acute respiratory tract 
infection for MERS coV and influenza viruses.
2. Methods
We screened Hajj and Umrah returnees from October 2014 to April 2015 for MERS-CoV 
and influenza virus infections; during this period Hajj occurred from October 1–6, 2014. In-
flight announcements for all airlines arriving from Mecca and landing at Srinagar airport 
were arranged for disembarking passengers, and advised pilgrims with current respiratory 
symptoms or fever to report to the medical team stationed in the arrival hall. Disembarking 
passengers were also questioned about the symptoms and enrolment in the study was offered 
to symptomatic passengers after their informed verbal consent. Data on demographics, 
symptoms, and history of prior influenza vaccination were recorded in a predefined case 
report form. Two swabs (nasopharyngeal and throat) were collected from each participant 
and pooled in viral transport media; and then transported to the laboratory in Sheri Kashmir 
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Institute of Medical Sciences (SKIMS) within 3–4 h of collection. Samples were tested by 
real-time reverse transcriptase polymerase chain reaction (PCR) for MERS-CoV using a 
WHO recommended protocol (targeting region upstream of E protein gene (upE) of MERS-
CoV [8]and influenza viruses. Patients with positive results for influenza viruses were 
contacted for assessment for therapy by the medical clinic at SKIMS or by respective 
physicians and treated if indicated. Descriptive statistics was used to assess various 
prevalence rates. Comparison of proportions was performed by SPSS (Statistical Package for 
Social Sciences) Version 17 software, IBM Limited, USA. Values have been expressed as 
percentages and a p-value of <0.05 was considered significant. The study was approved by 
the Institute Ethics Committee of SKIMS.
3. Results
Of the 8753 pilgrims, 977 (11.2%) reported symptoms of fever and/or respiratory symptoms 
and 300 (31%) consented to participate in the study. Participants’ median age was 60 years 
(range 26–90 years) and 140 (47%) were male. Participants had been in Saudi Arabia for 
21–42 days (median 40 days) and reported symptoms of 1–15 days duration (median 5 days) 
(Table 1). Cough (89.7%) and nasal discharge (86.3%) were the most commonly reported 
symptoms. None of the 300 participants tested positive for MERS-CoV; however, 33 (11%) 
participants aged 37–86 years tested positive for influenza viruses (A/H3N2 = 13), A/
H1N1pdm09 = 9 and B/Yamagata = 11). Influenza positive cases had a significantly higher 
frequency of fever, rigors, and chills than influenza test-negatives (Table 1). All influenza 
positive cases were asked to follow-up at the study-hospital based-clinic and advised about 
infection control. Sixteen (48%) patients reported back to the study clinic and were 
prescribed oral oseltamivir. Seventeen (52%) patients who did not reach the hospital clinic 
were advised to seek medical help locally and the reports were conveyed to their physicians; 
two were prescribed oseltamivir. There is no state policy for use of influenza antivirals, 
however the common practice is to prescribe oseltamivir during an influenza season for 
suspected influenza cases who appear sick and febrile without waiting for laboratory 
confirmation. No hospitalizations were needed and all had uneventful recovery over a period 
of 2–5 days (median 5 d).
Of the 300 participants, 216 (72%) reported receiving inactivated influenza vaccine 
(comprising of A/California/7/2009 (H1N1) pdm09-like virus; A/Texas/50/2012 (H3N2)-
like virus and B/Mas-sachusetts/2/2012 (Yamagata)-like virus) approximately 2 weeks 
(median 16 days, range 14–21days) prior to the pilgrimage. About 10% (n = 21) of the these 
tested positive for influenza in comparison to 14.3% (n = 12) of those not vaccinated prior to 
the pilgrimage (p = 0.26). No differences in age, gender, onset or frequency of symptoms 
were seen between vaccinees who tested positive and those who tested negative for 
influenza. Some of the participants also gave a history of spontaneous recovery from their 
respiratory illness that they had developed while in Saudi Arabia. However there was no 
record of any laboratory confirmation for any bacterial or a viral pathogen having caused the 
illness.
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4. Discussion
Peak travel periods to Saudi Arabia (e.g., Ramadan, Umrah, or the Hajj) are of concern for 
the spread of respiratory viruses, including influenza and MERS-CoV, and the Saudi 
Government recommends pre-travel influenza vaccination [9,10]. The normal influenza 
season in Kashmir occurs during January-April [11]; thus, even before Hajj, many of the 
pilgrims, especially the elderly are at high-risk for influenza illness and its complications. 
The Hajj in 2014 drew more than 2 million travelers at a time when Saudi Arabia’s capital 
was battling a large hospital-linked MERS-CoV outbreak with smaller clusters recently 
detected elsewhere, including the holy city of Medina [2,3].
In the current study, vaccination against influenza had no significant effect on confirmed 
influenza. Additionally no differences in age, gender, onset or frequency of symptoms were 
seen between vaccinees who tested positive and those who tested negative for influenza. 
Assuming self-report correctly characterized vaccination status, the occurrence of influenza 
cases among those vaccinated especially the elderly needs to be studied further.
Despite a high prevalence of acute respiratory illness (ARI) among returning pilgrims from 
Saudi Arabia, none of the 300 (one-sided 97.5% CI 1.2) study participants with ARI tested 
positive for MERS-CoV.. Although we only screened one-third of ill travelers, our data is 
compatible with earlier reports in which no MERS-CoV cases were identified in Hajj 
returnees [12,13] in other countries outside of India. In another large study involving 5235 
adult Hajj pilgrims from 22 countries, including 3 with reports of MERS Co–V and those 
with geographic proximity to Saudi Arabia, there was no evidence of MERS-CoV nasal 
carriage among Hajj pilgrims (3210 pre-Hajj, 2025 post-Hajj) which could supporting poor 
or moderate interhuman transmission, despite the pilgrims having stayed in close contact 
with persons with respiratory symptoms [14]. Our findings demonstrated the risk of 
influenza among travellers returning from such mass gatherings which therefore requires 
continued health awareness on vaccination and other preventive measures.
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Table 1
Comparative symptoms in Influenza positive and influenza negative pariticipants.
Symptoms & Signs Influenza positive N = 33 Influenza negative N = 267 p-value
Fever 24 (72.7) 133 (49.8) 0.015
Chills and Rigors 18 (54.5) 96 (35.9) 0.04
Nasal discharge 30 (90.9) 229 (85.7) 0.41
Ear discharge 1 (3.0) 4 (1.5) 0.53
Cough 29 (87.8) 240 (89.8) 0.72
Sore throat 19 (57.5) 177 (66.2) 0.32
Breathlessness 11 (33.3) 69 (25.8) 0.36
Exectoration 10 (30.3) 65 (24.3) 0.45
Headache 19 (57.5) 137 (51.3) 0.50
Bodyache 20 (60.6) 145 (54.3) 0.49
Fatigue 16 (48.4) 132 (49.4) 0.91
Vomiting 2 (6.1) 10 (3.7) 0.50
Diarrhea 2 (6.1) 8 (3.0) 0.35
Seizures 1 (3.0) 2 (0.8) 0.24
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